Posts Tagged: "Medical technologies"

Samsung patent totals top 2,000 in Q1 2016, invents foldable and rollable electronic display screens

In 2015, Samsung Electronics earned a total of 5,072 patents from the U.S. Patent and Trademark Office, a slight increase from the 4,936 U.S. patents which the company took home in 2014. Including design and utility patents, Samsung has already taken in 2,017 U.S. patents since the beginning of 2016, an incredible pace which would blow past the firm’s 2015 totals if it holds up all year. As the text cluster from Innography shows us here, much of this recent research and development has focused on semiconductor devices, memory devices and display panels.

Amici led by Eli Lilly file brief in Supreme Court in support of Sequenom certiorari petition

Rather than use the word ‘conflate’ to describe the mongrel mixture of patentability requirements the Supreme Court undertook in Mayo, the Eli Lilly brief characterizes the analysis employed by the Supreme Court as including a separate, implicit ‘threshold test’ for patentability that is applied even before consideration of the statutory patentability requirements. Eli Lilly hypothesizes that this ‘implicit exception was imposed to assure that patents cannot validly protect—or preempt access to—laws of nature, natural phenomena, or abstract ideas.’

Injectable migraine treatment being developed by Alder, Eli Lilly, Amgen and others

Migraines are the result of a hereditary neurological disorder which causes certain areas of the brain to become over-excited, creating the throbbing pain and increased sensitivity to lights, smells or sounds which characterize a migraine attack. Not much is known about the brain chemistry that directly causes a migraine, although it’s generally understood that hormonal fluctuations or environmental stimuli can act as triggers. News of successful mid-stage trials for a migraine treatment developed by Alder Biopharmaceuticals Inc. has been greeted with a warm welcome from news media. The results of the trial show that an injectable treatment known as ALD403 administered four times over the course of a year reduced patient suffering from chronic migraines.

Abbott Labs acquires large Alere patent portfolio in $5.8 billion deal, increasing diagnostic lineup

Abbott Laboratories (NYSE:ABT) of Chicago, IL, is poised to surge ahead in the global point-of-care medical diagnostics industry by acquiring Alere Inc. (NYSE:ALR) of Waltham, MA, in a $5.8 billion deal which values Alere at $56 per share. According a recent statement made by Abbott CEO Miles White to investors, the move will push the company’s annual diagnostic sales up to $7 billion. The acquisition is simply the latest major move in the medical device industry, a sector which saw more than 1,000 deals pending or completed last year for a net worth of $58.9 billion, according to statistics published by Bloomberg Business.

In midst of stiff corporate headwinds, Toshiba maintains spot as leading innovator

Toshiba exists among the giants of the U.S. patent landscape, placing sixth among all companies in terms of patents received from the U.S. Patent and Trademark Office in 2015; it took home 2,627 U.S. patents in 2015. This sixth-place showing sees Toshiba improving upon its 2014 rankings, where it took in the seventh-most U.S. patents. In terms of total U.S. patents, however, Toshiba actually earned less than it did in 2014, when it brought in 2,850 patents. In the three months leading up to this writing, Toshiba earned 677 U.S. patents, according to Innography’s patent portfolio analysis tools. The text cluster indicates that there remains a great deal of focus on developing semiconductor layer and memory technologies at Toshiba, although activities in control units, image processing and image data are also prominent.